Gene transfer: the challenge of regulated gene expression
暂无分享,去创建一个
B. Fang | Z. Guo | D. Bartlett | Qiang Li | Z Sheng Guo | Bingliang Fang | David L Bartlett | James Y. Yang | James Y Yang | Qiang Li
[1] M. Fussenegger,et al. An engineered epigenetic transgene switch in mammalian cells , 2004, Nature Biotechnology.
[2] Akseli Hemminki,et al. Tissue-specific promoters for cancer gene therapy , 2004, Expert opinion on biological therapy.
[3] M. DePamphilis,et al. Specific transcription factors stimulate simian virus 40 and polyomavirus origins of DNA replication , 1992, Molecular and cellular biology.
[4] D. Nettelbeck,et al. Insulated hsp70B′ promoter: stringent heat‐inducible activity in replication‐deficient, but not replication‐competent adenoviruses , 2008, The journal of gene medicine.
[5] Jonathan L. Linehan,et al. Efficient and Stable Transgene Expression in Human Embryonic Stem Cells Using Transposon‐Mediated Gene Transfer , 2007, Stem cells.
[6] J. Gu,et al. Augmenting transgene expression from carcinoembryonic antigen (CEA) promoter via a GAL4 gene regulatory system. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[7] C. Halbert,et al. High-efficiency promoter-dependent transduction by adeno-associated virus type 6 vectors in mouse lung. , 2007, Human gene therapy.
[8] M. Kanaoka,et al. Expression of pIX gene induced by transgene promoter: possible cause of host immune response in first-generation adenoviral vectors. , 2007, Human gene therapy.
[9] L Ji,et al. A binary adenoviral vector system for expressing high levels of the proapoptotic gene bax , 2000, Gene Therapy.
[10] J. Rivas,et al. Interleukin-12 inhibits liver-specific drug-inducible systems in vivo , 2008, Gene Therapy.
[11] Resveratrol is an effective inducer of CArG-driven TNF-α gene therapy , 2008, Cancer Gene Therapy.
[12] N. Knuckey,et al. Assessment of CMV, RSV and SYN1 promoters and the woodchuck post-transcriptional regulatory element in adenovirus vectors for transgene expression in cortical neuronal cultures , 2006, Brain Research.
[13] T. Fujiwara,et al. Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter. , 2008, Uirusu.
[14] Hongyan Dong,et al. Hypoxic response elements control expression of human vascular endothelial growth factor165 genes transferred to ischemia myocardium in vivo and in vitro , 2007, The journal of gene medicine.
[15] Jane Worthington,et al. p21(WAF1)-mediated transcriptional targeting of inducible nitric oxide synthase gene therapy sensitizes tumours to fractionated radiotherapy , 2007, Gene Therapy.
[16] A. Annoni,et al. Immune responses to lentiviral vectors. , 2007, Current gene therapy.
[17] P. Overbeek,et al. Tissue-specific expression in transgenic mice of a fused gene containing RSV terminal sequences. , 1986, Science.
[18] M. Lotze,et al. Second‐generation tetracycline‐regulatable promoter: repositioned tet operator elements optimize transactivator synergy while shorter minimal promoter offers tight basal leakiness , 2004, The journal of gene medicine.
[19] G. Rubanyi,et al. Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle , 2004, The journal of gene medicine.
[20] J. Mallet,et al. Lentiviral vectors mediate nonimmunosuppressive rapamycin analog-induced production of secreted therapeutic factors in the brain: regulation at the level of transcription and exocytosis. , 2008, Human gene therapy.
[21] K. Jooss,et al. An antibody delivery system for regulated expression of therapeutic levels of monoclonal antibodies in vivo. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[22] B. Geest,et al. Direct comparison of hepatocyte-specific expression cassettes following adenoviral and nonviral hydrodynamic gene transfer , 2008, Gene Therapy.
[23] A. Kingsman,et al. An adenoviral vector regulated by hypoxia for the treatment of ischaemic disease and cancer , 1999, Gene Therapy.
[24] R. Martuza,et al. Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector. , 2006, Cancer research.
[25] T. Fujiwara,et al. Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter. , 2007, Current cancer drug targets.
[26] J. Paton,et al. Enhancement of cell-specific transgene expression from a Tet-Off regulatory system using a transcriptional amplification strategy in the rat brain , 2008, The journal of gene medicine.
[27] P. Friedlander,et al. Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promoter causes tumor-selective tumor lysis. , 2003, Cancer research.
[28] Rong Li,et al. Construction of an artificial intercellular communication network using the nitric oxide signaling elements in mammalian cells. , 2008, Experimental cell research.
[29] Jun Ma,et al. GAL4-VP16 is an unusually potent transcriptional activator , 1988, Nature.
[30] N. Nakatsuji,et al. Establishment of the Gene‐Inducible System in Primate Embryonic Stem Cell Lines , 2006, Stem cells.
[31] S. Kasparov,et al. GAL4-NF-kappaB fusion protein augments transgene expression from neuronal promoters in the rat brain. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[32] R. Mandel,et al. Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions. , 2007, Current gene therapy.
[33] M. Oshimura,et al. Correction of a genetic defect in multipotent germline stem cells using a human artificial chromosome , 2008, Gene Therapy.
[34] M. Carey,et al. Configurations of a two-tiered amplified gene expression system in adenoviral vectors designed to improve the specificity of in vivo prostate cancer imaging , 2008, Gene Therapy.
[35] Su-Chun Zhang,et al. Transgenes delivered by lentiviral vector are suppressed in human embryonic stem cells in a promoter-dependent manner. , 2007, Stem cells and development.
[36] Erwin G. Van Meir,et al. Erratum: Targeted cancer gene therapy using a hypoxia inducible factor-dependent oncolytic adenovirus armed with interleukin-4 (Cancer Research (2007) 67, (6872-6881)) , 2007 .
[37] D. Bartlett,et al. Development of a melanoma-specific adenovirus. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.
[38] George Q. Daley,et al. Prospects for Stem Cell-Based Therapy , 2008, Cell.
[39] M. Oshimura,et al. Human artificial chromosome vectors meet stem cells: new prospects for gene delivery. , 2006, Stem cell reviews.
[40] Erwin G. Van Meir,et al. Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4. , 2007, Cancer research.
[41] S. Kyo,et al. A novel telomerase-specific gene therapy: gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter. , 2000, Human gene therapy.
[42] Knut Stieger,et al. Immune responses to gene product of inducible promoters. , 2007, Current gene therapy.
[43] R. Cortese,et al. Gene therapy progress and prospects: transcription regulatory systems , 2004, Gene Therapy.
[44] E. Lou,et al. An oncolytic mutant of herpes simplex virus type-1 in which replication is governed by a promoter/enhancer of human papillomavirus type-16 , 2007, Cancer Gene Therapy.
[45] Zhao-hui Peng,et al. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. , 2005, Human gene therapy.
[46] T. Akhurst,et al. Tumor-specific transcriptional targeting of suicide gene therapy , 2002, Gene Therapy.
[47] D. Hallahan,et al. Ionizing radiation activates transcription of the EGR1 gene via CArG elements. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[48] P. Cannon,et al. Promoter choice for retroviral vectors: transcriptional strength versus trans-activation potential. , 2007, Human gene therapy.
[49] J. Bruder,et al. Promoters influence the kinetics of transgene expression following adenovector gene delivery , 2008, The journal of gene medicine.
[50] H. Mizuguchi,et al. Efficient gene transfer into mouse embryonic stem cells with adenovirus vectors. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[51] V. Sandig,et al. Reactivation of the Previously Silenced Cytomegalovirus Major Immediate-Early Promoter in the Mouse Liver: Involvement of NFκB , 1998, Journal of Virology.
[52] R. Weichselbaum,et al. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] S. Scott,et al. The radiation-inducible pE9 promoter driving inducible nitric oxide synthase radiosensitizes hypoxic tumour cells to radiation , 2008, Gene Therapy.
[54] Douglas B. Evans,et al. Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models. , 2007, Cancer cell.
[55] Y Wang,et al. A regulatory system for use in gene transfer. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[56] K. Jooss,et al. Stable antibody expression at therapeutic levels using the 2A peptide , 2005, Nature Biotechnology.
[57] K. Matthaei. Genetically manipulated mice: a powerful tool with unsuspected caveats , 2007, The Journal of physiology.
[58] Melisa L. Budde,et al. Generation and characterization of novel tetracycline-inducible pancreatic transcription factor-expressing murine embryonic stem cell lines. , 2006, Stem cells and development.
[59] Matthias Schieker,et al. Introducing a single-cell-derived human mesenchymal stem cell line expressing hTERT after lentiviral gene transfer , 2008, Journal of cellular and molecular medicine.
[60] D. Nettelbeck,et al. Analyses of melanoma-targeted oncolytic adenoviruses with tyrosinase enhancer/promoter-driven E1A, E4, or both in submerged cells and organotypic cultures. , 2004, Molecular cancer therapeutics.
[61] M. Dewhirst,et al. A phase I trial of hyperthermia-induced interleukin-12 gene therapy in spontaneously arising feline soft tissue sarcomas , 2007, Molecular Cancer Therapeutics.
[62] N. Senzer,et al. TNFerade, an Adenovector Carrying the Transgene for Human Tumor Necrosis Factor α, for Patients With Advanced Solid Tumors: Surgical Experience and Long-Term Follow-Up , 2005, Annals of Surgical Oncology.
[63] N. Vilaboa,et al. Regulatable gene expression systems for gene therapy. , 2006, Current gene therapy.
[64] Shannon R. Magari,et al. A humanized system for pharmacologic control of gene expression , 1996, Nature Medicine.
[65] Hoguen Kim,et al. Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. , 2003, Human gene therapy.
[66] Sinae Kim,et al. Efficiency of the elongation factor-1alpha promoter in mammalian embryonic stem cells using lentiviral gene delivery systems. , 2007, Stem cells and development.
[67] E. Chiocca,et al. Oncolytic viruses driven by tumor-specific promoters. , 2007, Current cancer drug targets.
[68] L. Wang,et al. Oncolysis and suppression of tumor growth by a GFP-expressing oncolytic adenovirus controlled by an hTERT and CMV hybrid promoter , 2006, Cancer Gene Therapy.
[69] Masa Tsuchiya,et al. Sequential Logic Model Deciphers Dynamic Transcriptional Control of Gene Expressions , 1997, PloS one.
[70] Su-Chun Zhang,et al. In Vitro‐ and In Vivo‐Induced Transgene Expression in Human Embryonic Stem Cells and Derivatives , 2008, Stem cells.
[71] S. Rocha. Gene regulation under low oxygen: holding your breath for transcription. , 2007, Trends in biochemical sciences.
[72] M. Manns,et al. A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. , 2003, Cancer research.
[73] R. Evans,et al. Ecdysone-inducible gene expression in mammalian cells and transgenic mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[74] P. Schlag,et al. Heat-inducible in vivo gene therapy of colon carcinoma by human mdr1 promoter–regulated tumor necrosis factor-α expression , 2007, Molecular Cancer Therapeutics.
[75] Soonsang Yoon,et al. Functional analysis of various promoters in lentiviral vectors at different stages of in vitro differentiation of mouse embryonic stem cells. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[76] H. Mizuguchi,et al. Efficient adenovirus vector‐mediated PPAR gamma gene transfer into mouse embryoid bodies promotes adipocyte differentiation , 2008, The journal of gene medicine.
[77] G. Fuller,et al. The neuronal repressor REST/NRSF is an essential regulator in medulloblastoma cells , 2000, Nature Medicine.
[78] K. Shirouzu,et al. An optimal therapeutic expression level is crucial for suicide gene therapy for hepatic metastatic cancer in mice , 2003, Hepatology.
[79] Ren-Ke Li,et al. Human CMV immediate‐early enhancer: a useful tool to enhance cell‐type‐specific expression from lentiviral vectors , 2008, The journal of gene medicine.
[80] Samuel Hellman,et al. Spatial and temporal control of gene therapy using ionizing radiation , 1995, Nature Medicine.
[81] P. Pasceri,et al. Retrovirus silencing, variegation, extinction, and memory are controlled by a dynamic interplay of multiple epigenetic modifications. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.
[82] S. Scott,et al. Hypoxia- and radiation-activated Cre/loxP ‘molecular switch’ vectors for gene therapy of cancer , 2006, Gene Therapy.
[83] A. Hochberg,et al. Use of transcriptional regulatory sequences of telomerase (hTER and hTERT) for selective killing of cancer cells. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.
[84] C. Barcia,et al. Regulatable gene expression systems for gene therapy applications: progress and future challenges. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[85] G. Vassaux,et al. Modulation of telomerase promoter tumor selectivity in the context of oncolytic adenoviruses. , 2007, Cancer research.
[86] H. Fang,et al. Clinical trials with oncolytic adenovirus in China. , 2007, Current cancer drug targets.
[87] I. Alexander,et al. Bidirectional promoter interference between two widely used internal heterologous promoters in a late-generation lentiviral construct , 2008, Gene Therapy.
[88] L. Wang,et al. Evaluation of promoter strength for hepatic gene expression in vivo following adenovirus-mediated gene transfer. , 1996, Gene therapy.
[89] R. Weichselbaum,et al. Transcriptional control of viral gene therapy by cisplatin. , 2002, The Journal of clinical investigation.
[90] J. Reiser,et al. Tight control of transgene expression by lentivirus vectors containing second‐generation tetracycline‐responsive promoters , 2005, The journal of gene medicine.
[91] Dexi Liu,et al. Evaluation of viral and mammalian promoters for driving transgene expression in mouse liver. , 2006, Biochemical and biophysical research communications.
[92] C. Heeschen,et al. Genetically engineered stem cells for therapeutic gene delivery. , 2007, Current gene therapy.
[93] Z. Guo,et al. Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. , 2008, Biochimica et biophysica acta.
[94] Focal Gene Induction in the Liver of Rats by a Heat-Inducible Promoter Using Focused Ultrasound Hyperthermia: Preliminary Results , 2005, Investigative radiology.
[95] M. Imhof,et al. Reversal of the silencing of tetracycline‐controlled genes requires the coordinate action of distinctly acting transcription factors , 2005, The journal of gene medicine.
[96] R. Weichselbaum,et al. Ionizing radiation: a genetic switch for cancer therapy , 2006, Cancer Gene Therapy.
[97] S. Orkin,et al. Site-directed, virus-free, and inducible RNAi in embryonic stem cells , 2007, Proceedings of the National Academy of Sciences.
[98] K. Irvine,et al. De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model. , 2006, Cancer research.
[99] I. Delgado-Enciso,et al. A potent replicative delta‐24 adenoviral vector driven by the promoter of human papillomavirus 16 that is highly selective for associated neoplasms , 2007, The journal of gene medicine.
[100] J. Gu,et al. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. , 2000, Cancer research.